Page 34 - CASA Bulletin of Anesthesiology 2022, Vol 9, No 1 (1)

CASA Bulletin of Anesthesiology

Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant
hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010 Feb 1; 110(2):498-507. doi:
10.1213/ANE.0b013e3181c6b9b2. PMID: 20081135.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007 Apr 24; 2:21. doi:
10.1186/1750-1172-2-21. PMID: 17456235; PMCID: PMC1867813.
Maclennan DH, Zvaritch E. Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum.
Biochim Biophys Acta. 2011 May;1813(5):948-64. doi: 10.1016/j.bbamcr.2010.11.009. Epub 2010 Nov 27. PMID: 21118704.
O'Sullivan GH, McIntosh JM, Heffron JJ. Abnormal uptake and release of Ca2+ ions from human malignant hyperthermia-
susceptible sarcoplasmic reticulum. Biochem Pharmacol. 2001 Jun 15;61(12):1479-85. doi: 10.1016/s0006-2952(01)00604-9.
PMID: 11377377.
Quane KA, Healy JM, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ording H, et al.
Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993 Sep;5(1):51-5.
doi: 10.1038/ng0993-51. PMID: 8220423.
Gronert GA, Theye RA. Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes.
Anesthesiology. 1976 Jan; 44(1):36-43. doi: 10.1097/00000542-197601000-00008. PMID: 1244773.
Mickelson JR, Louis CF. Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+
regulation defects. Physiol Rev. 1996 Apr;76(2):537-92. doi: 10.1152/physrev.1996.76.2.537. PMID: 8618963.
http://www.mhaus.org/ (Malignant Hyperthermia Association of the United States)
https://www.aaaasf.org/ (American Association for Accreditation of Ambulatory Surgery Facilities)
Louis CF, Zualkernan K, Roghair T, Mickelson JR. The effects of volatile anesthetics on calcium regulation by malignant
hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology. 1992 Jul; 77(1):114-25. doi: 10.1097/00000542-
199207000-00017. PMID: 1609985.
Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982 Apr;56(4):254-62. doi:
10.1097/00000542-198204000-00005. PMID: 7039419.
Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014
Feb;118 (2):388-396. doi: 10.1213/ANE.0000000000000062. PMID: 24445637.
Joshi GP, Desai MS, Gayer S, Vila H Jr; Society for Ambulatory Anesthesia (SAMBA). Succinylcholine for Emergency Airway
Rescue in Class B Ambulatory Facilities: The Society for Ambulatory Anesthesia Position Statement. Anesth Analg. 2017
May;124(5):1447-1449. doi: 10.1213/ANE.0000000000001682. PMID: 27984222.
Glahn KPE, Bendixen D, Girard T, Hopkins PM, Johannsen S, Rüffert H, Snoeck MM, Urwyler A; European Malignant
Hyperthermia Group. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant
Hyperthermia Group guidelines. Br J Anaesth. 2020 Aug;125(2):133-140. doi: 10.1016/j.bja.2020.04.089. Epub 2020 Jun 24.
PMID: 32591088.
Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia: an analysis of cases from the
North American Malignant Hyperthermia Registry. Anesthesiology. 2008 Nov;109 (5):825-9. doi:
10.1097/ALN.0b013e31818958e5. PMID: 18946294.
Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant
hyperthermia reactions. Anesthesiology. 2007 May;106 (5):901-6; quiz 1077-8. doi: 10.1097/01.anes.0000265148.86566.68.
PMID: 17457120.
Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, et
al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994 Apr;80(4):771-9. doi:
10.1097/00000542-199404000-00008. PMID: 8024130.
Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate
temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant
hyperthermia association of the United States. Anesth Analg. 2014 Dec;119(6):1359-66. doi:
10.1213/ANE.0000000000000421. PMID: 25268394.
Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to
2005. Anesthesiology. 2009 Jan;110 (1):89-94. doi: 10.1097/ALN.0b013e318190bb08. PMID: 19104175.
Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac arrests and deaths associated with malignant
hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the
malignant hyperthermia association of the United States. Anesthesiology. 2008 Apr;108(4):603-11. doi:
10.1097/ALN.0b013e318167aee2. PMID: 18362591.
Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982 Apr;56(4):254-62. doi:
10.1097/00000542-198204000-00005. PMID: 7039419.
https://www.mhaus.org/healthcare-professionals/be-prepared/what-should-be-on-an-mh-cart/

P a g e 33 | 60